Fig. 4From: Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapsesEstimated effectiveness for the three alternatives. The posterior median values were 0.64, 0.47 and 0.34 for high-dose methylprednisolone, low-dose methylprednisolone and placebo, respectivelyBack to article page